Cargando…

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines

The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis. Sevente...

Descripción completa

Detalles Bibliográficos
Autores principales: Subik, Kristina, Lee, Jin-Feng, Baxter, Laurie, Strzepek, Tamera, Costello, Dawn, Crowley, Patti, Xing, Lianping, Hung, Mien-Chie, Bonfiglio, Thomas, Hicks, David G., Tang, Ping
Formato: Texto
Lenguaje:English
Publicado: Libertas Academica 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914277/
https://www.ncbi.nlm.nih.gov/pubmed/20697531
_version_ 1782184749535592448
author Subik, Kristina
Lee, Jin-Feng
Baxter, Laurie
Strzepek, Tamera
Costello, Dawn
Crowley, Patti
Xing, Lianping
Hung, Mien-Chie
Bonfiglio, Thomas
Hicks, David G.
Tang, Ping
author_facet Subik, Kristina
Lee, Jin-Feng
Baxter, Laurie
Strzepek, Tamera
Costello, Dawn
Crowley, Patti
Xing, Lianping
Hung, Mien-Chie
Bonfiglio, Thomas
Hicks, David G.
Tang, Ping
author_sort Subik, Kristina
collection PubMed
description The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis. Seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks. IHC analyses were performed on each cell block with antibodies to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, CK5/6, Ki-67 and androgen receptor (AR). Among the 17 cell lines, MCF-7 and ZR-75-1 fell to Luminal A subtype; BT-474 to Luminal B subtype; SKBR-3, MDA-MD-435 and AU 565 to HER2 over-expression subtype; MDA-MB-231, MCF-12A, HBL 101, HS 598 T, MCF-10A, MCF-10F, BT-20, 468 and BT-483 to basal subtype. MDA-MB-453 belonged to Unclassified subtype. Since each subtype defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing a cell line for any study.
format Text
id pubmed-2914277
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-29142772010-08-09 The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines Subik, Kristina Lee, Jin-Feng Baxter, Laurie Strzepek, Tamera Costello, Dawn Crowley, Patti Xing, Lianping Hung, Mien-Chie Bonfiglio, Thomas Hicks, David G. Tang, Ping Breast Cancer (Auckl) Original Research The molecular classification for breast carcinomas has been used in clinical studies with a simple surrogate panel of immunohistochemistry (IHC) markers. The objective of this current project was to study the molecular classification of commonly used breast cancer cell lines by IHC analysis. Seventeen breast cancer cell lines were harvested, fixed in formalin and made into cell blocks. IHC analyses were performed on each cell block with antibodies to estrogen receptor (ER), progesterone receptor (PR), HER2, EGFR, CK5/6, Ki-67 and androgen receptor (AR). Among the 17 cell lines, MCF-7 and ZR-75-1 fell to Luminal A subtype; BT-474 to Luminal B subtype; SKBR-3, MDA-MD-435 and AU 565 to HER2 over-expression subtype; MDA-MB-231, MCF-12A, HBL 101, HS 598 T, MCF-10A, MCF-10F, BT-20, 468 and BT-483 to basal subtype. MDA-MB-453 belonged to Unclassified subtype. Since each subtype defined by this IHC-based molecular classification does show a distinct clinical outcome, attention should be paid when choosing a cell line for any study. Libertas Academica 2010-05-20 /pmc/articles/PMC2914277/ /pubmed/20697531 Text en © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
spellingShingle Original Research
Subik, Kristina
Lee, Jin-Feng
Baxter, Laurie
Strzepek, Tamera
Costello, Dawn
Crowley, Patti
Xing, Lianping
Hung, Mien-Chie
Bonfiglio, Thomas
Hicks, David G.
Tang, Ping
The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
title The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
title_full The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
title_fullStr The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
title_full_unstemmed The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
title_short The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
title_sort expression patterns of er, pr, her2, ck5/6, egfr, ki-67 and ar by immunohistochemical analysis in breast cancer cell lines
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914277/
https://www.ncbi.nlm.nih.gov/pubmed/20697531
work_keys_str_mv AT subikkristina theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT leejinfeng theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT baxterlaurie theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT strzepektamera theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT costellodawn theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT crowleypatti theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT xinglianping theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT hungmienchie theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT bonfigliothomas theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT hicksdavidg theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT tangping theexpressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT subikkristina expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT leejinfeng expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT baxterlaurie expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT strzepektamera expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT costellodawn expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT crowleypatti expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT xinglianping expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT hungmienchie expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT bonfigliothomas expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT hicksdavidg expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines
AT tangping expressionpatternsoferprher2ck56egfrki67andarbyimmunohistochemicalanalysisinbreastcancercelllines